Omeros Corporation (Nasdaq:OMER), a clinical-stage biopharmaceutical company, said on Tuesday that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs), namely GPR15, GPR39, GPR78 and GPR161.
GPR15 has been associated with rheumatoid arthritis and HIV-mediated enteropathy, GPR39 has been implicated in the pathogenesis of obesity-related type-2 diabetes and oesophageal squamous cell carcinoma, GPR78 has been linked to bipolar affective disorder and schizophrenia and GPR161 has been tied to congenital cataracts and birth defects of the brain and spinal cord.